Compliance

By Alvin J. Lorman, AAHP Counsel The lawsuit filed last October challenging FDA’s characterization of homeopathic products as unapproved new drugs will not be decided before the second quarter of…

By Mark Land, MS, RAC-US, AAHP President As 2024 comes to a close, let’s reflect on some of the news related to homeopathy and AAHP’s achievements. General News Affecting Homeopathy…

By Alissa Gould, Boiron USA Director of Communication and Public Affairs Over-the-counter homeopathic cough and cold products were the subject of a study to see if applying natural language processing…

By Mark Land, MS, RAC-US, AAHP President With all eyes on Washington this month, I would like to take this opportunity to give readers a glance at AAHP’s federal relations…

By Mark Land, MS, RAC-US, AAHP President The first time I read the drug GMP regulations at 21 CFR 210 & 211, I thought to myself: “This is common sense.…

By William Shevin, M.D., President, HPCUS, and Eric L. Foxman, Pharm. (Ret.), Senior Scientist, HPCUS. The Homeopathic Pharmacopeia Convention of the United States (HPCUS) has made note of current Good…

By Eric Foxman, Pharm. (Ret.) Current Good Manufacturing Practices (CGMPs) in 21CFR parts 210 and 211 provide a foundation for requisite quality steps during the entire pharmaceutical production process. Because…

By Mark Land, MS, RAC-US, AAHP President Each year one issue of the AAHP newsletter focuses on research. The March 2023 issue delved into basic and clinical research, as well…

The homeopathic industry has seen significant growth and increased visibility, bringing with it increased scrutiny from regulatory bodies like the U.S. Food and Drug Administration (FDA). To thrive in this…

By Mark Land, MS, RAC-US, AAHP President In 2016 I wrote an article on labeling homeopathic drug products for self-medication. At that time, I reported that there were more than…